QJBIOCH(SH:600796)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 387,754,555.29, representing a year-on-year increase of 17.25%[5] - The net profit attributable to shareholders was CNY 35,556,632.88, showing a significant increase of 1,895.59% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 24,947,495.90, up by 364.32% year-on-year[5] - Basic earnings per share reached CNY 0.04, reflecting a substantial increase of 566.67%[5] - Operating profit for Q1 2022 was RMB 38.79 million, significantly up from RMB 4.36 million in the same period last year[17] - Net profit for Q1 2022 was RMB 31.98 million, compared to a net loss of RMB 2.06 million in Q1 2021, marking a turnaround[17] - The total revenue for Q1 2022 reached RMB 387.75 million, an increase of 16.9% compared to RMB 330.70 million in Q1 2021[16] - The total comprehensive income for Q1 2022 was approximately ¥31.98 million, a decrease from ¥34.08 million in Q1 2021[22] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 23,905,233.68, an increase of 43.30% compared to the previous year[5] - The net cash flow from operating activities for Q1 2022 was ¥23.91 million, a significant improvement compared to a net outflow of ¥59.95 million in Q1 2021[21] - The net cash flow from investing activities for Q1 2022 was a negative ¥40.46 million, an improvement from a negative ¥300.96 million in Q1 2021[21] - The net cash flow from financing activities for Q1 2022 was a negative ¥3.25 million, compared to a positive ¥326.17 million in Q1 2021[22] - Current liabilities decreased to RMB 1.46 billion from RMB 1.64 billion at the end of 2021, reflecting improved liquidity[14] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,371,611,642.05, a decrease of 1.83% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 6.37 billion, a decrease from RMB 6.49 billion at the end of 2021[15] - The total liabilities decreased to RMB 3.04 billion from RMB 3.19 billion at the end of 2021, indicating a reduction in financial leverage[15] - The equity attributable to shareholders increased to RMB 2.93 billion from RMB 2.89 billion at the end of 2021, reflecting a strengthening balance sheet[15] Shareholder Information - The company reported a total of 26,046 common shareholders at the end of the reporting period[10] Non-Recurring Gains - Non-recurring gains totaled CNY 10,609,136.98, with significant contributions from asset disposals and government subsidies[7] Research and Development - Research and development expenses for Q1 2022 were RMB 6.77 million, down from RMB 8.05 million in Q1 2021, suggesting a focus on cost management[17] Sales and Revenue - The increase in net profit was primarily driven by higher profit margins on biochemical products and increased sales revenue[8] - The company received cash from sales of goods and services amounting to approximately ¥529.40 million in Q1 2022, compared to ¥485.41 million in Q1 2021[20] - Inventory increased to RMB 152.36 million, up from RMB 111.70 million at the end of 2021, indicating potential growth in sales[14] Investment Income - The company reported an investment income of RMB 16.68 million in Q1 2022, a significant increase from RMB 0.03 million in Q1 2021[17] Return on Equity - The return on equity (ROE) increased to 1.23%, up by 1.13 percentage points from the previous year[6] Cash and Cash Equivalents - The cash and cash equivalents at the end of Q1 2022 were approximately ¥838.75 million, a decrease from ¥858.54 million at the beginning of the quarter[22] Tax Refunds - The company reported a decrease in cash received from tax refunds, totaling ¥3.56 million in Q1 2022, down from ¥5.26 million in Q1 2021[21]